Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type (Oral & Parenteral Antibiotics and Topical Antibiotics), By Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), By Route of Administration (Oral, Parenteral, Topi

Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type (Oral & Parenteral Antibiotics and Topical Antibiotics), By Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.

Market Dynamics:

Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2019, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.

Detailed Segmentation-

• By Drug Type:
• Oral & Parenteral Antibiotics
• Oritavancin
• Delafloxacin
• Vancomycin
• Others
• Topical Antibiotics
• Hydrogen Peroxide
• Fusidic Acid
• Mupirocin
• Retapamulin
• By Infection Type:
• Hospital Acquired ABSSSI
• Community Acquired ABSSSI
• By Route of Administration:
• Oral
• Parenteral
• Topical
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Fresenius SE & Co. KGaA
• Pfizer, Inc.
• Amneal Pharmaceuticals LLC
• Intas Pharmaceuticals Ltd.
• Cadila Healthcare Ltd.
• Glenmark Pharmaceuticals Ltd
• GSK plc
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• AbbVie, Inc.
• Melinta Therapeutics, Inc.
• Accord Healthcare Ltd.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Paratek Pharmaceuticals, Inc.